Eric Karran (Cambridge), Manuela Graziani (Roma), Marion Haberkamp ,
MicroRNA (miRNA) speciation in Alzheimer's disease (AD) cerebrospinal fluid (CSF) and extracellular fluid (ECF), Int. J. Biochem. Mol. Biol, vol.3, pp.365-373, 2012. ,
Utility of neuronal-derived exosomes to examine molecular mechanisms that affect motor function in patients with parkinson disease: a secondary analysis of the exenatide-pd trial, JAMA Neurol, 2019. ,
Circulating miR-150 in CSF is a novel candidate biomarker for multiple sclerosis, Neurol. Neuroimmunol. Neuroinflamm, vol.3, p.219, 2016. ,
Biomarkers in Alzheimer's disease drug development, Alzheimers Dement, vol.7, 2011. ,
Cancer precision medicine: from cancer screening to drug selection and personalized immunotherapy, Trends Pharmacol. Sci, vol.38, pp.15-24, 2017. ,
Efficacy of larotrectinib in trk fusion-positive cancers in adults and children, N. Engl. J. Med, vol.378, pp.731-739, 2018. ,
Neural-derived extracellular vesicles in clinical trials: message in a bottle, JAMA Neurol, 2019. ,
In a randomized trial in prostate cancer patients, dietary protein restriction modifies markers of leptin and insulin signaling in plasma extracellular vesicles, Aging Cell, vol.16, pp.1430-1433, 2017. ,
Plasma amyloid beta 42/40 ratios as biomarkers for amyloid beta cerebral deposition in cognitively normal individuals, pp.179-187, 2017. ,
Sex differences in Alzheimer diseasethe gateway to precision medicine, Nat. Rev. Neurol, vol.14, pp.457-469, 2018. ,
Identification of preclinical Alzheimer's disease by a profile of pathogenic proteins in neurally derived blood exosomes: a case-control study, Alzheimers Dement, vol.11, pp.600-607, 2015. ,
Use of quantitative clinical pharmacology to improve early clinical development success in neurodegenerative diseases, Expert Rev. Clin. Pharmacol, vol.11, pp.789-795, 2018. ,
Assessing the synergy between cholinomimetics and memantine as augmentation therapy in cognitive impairment in schizophrenia. A virtual human patient trial using quantitative systems pharmacology, Front. Pharmacol, vol.6, p.198, 2015. ,
Going to the negative: genomics for optimized medical prescription, Nat. Rev. Genet, vol.20, pp.1-2, 2019. ,
Cargo proteins of plasma astrocyte-derived exosomes in Alzheimer's disease, FASEB J, vol.30, pp.3853-3859, 2016. ,
Altered cargo proteins of human plasma endothelial cell-derived exosomes in atherosclerotic cerebrovascular disease, FASEB J, vol.31, pp.3689-3694, 2017. ,
Declining levels of functionally specialized synaptic proteins in plasma neuronal exosomes with progression of Alzheimer's disease, FASEB J, vol.32, pp.888-893, 2018. ,
High complement levels in astrocyte-derived exosomes of Alzheimer disease, Ann. Neurol, vol.83, pp.544-552, 2018. ,
The FDA oncology center of excellence and precision medicine, Exp. Biol. Med, vol.243, pp.308-312, 2018. ,
Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic, Nat. Rev. Neurol, vol.14, pp.639-652, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-01972372
Revolution of alzheimer precision neurology. passageway of systems biology and neurophysiology, J. Alzheimers. Dis, vol.64, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-01910402
Alzheimer's disease biomarker-guided diagnostic workflow using the added value of six combined cerebrospinal fluid candidates: abeta1-42, totaltau, phosphorylated-tau, NFL, neurogranin, and YKL-40, Alzheimers Dement, vol.14, pp.492-501, 2018. ,
Precision pharmacology for Alzheimer's disease, Pharmacol. Res, vol.130, pp.331-365, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-02095292
Current and future perspectives of liquid biopsies in genomics-driven oncology, Nat. Rev. Genet, vol.20, pp.71-88, 2019. ,
A/T/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers, Neurology, vol.87, pp.539-547, 2016. ,
Companion diagnostics-a tool to improve pharmacotherapy, Ann. Transl. Med, vol.4, p.482, 2016. ,
New frontiers in druggability, J. Med. Chem, vol.58, pp.9063-9088, 2015. ,
Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease, Alzheimers Dement, vol.11, pp.1180-1190, 2015. ,
Association of plasma neurofilament light with neurodegeneration in patients with alzheimer disease, JAMA Neurol, vol.74, pp.557-566, 2017. ,
Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau-and amyloid-positron emission tomography, Alzheimers Dement, vol.14, pp.989-997, 2018. ,
Distinctive behaviors of druggable proteins in cellular networks, PLoS Comput. Biol, vol.11, 2015. ,
Current state of Alzheimer's fluid biomarkers, Acta Neuropathol, vol.136, pp.821-853, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-01960281
Plasma extracellular vesicles enriched for neuronal origin: a potential window into brain pathologic processes, Front. Neurosci, vol.11, p.278, 2017. ,
High performance plasma amyloid-beta biomarkers for Alzheimer's disease, Nature, vol.554, pp.249-254, 2018. ,
Whole-exome sequencing and imaging genetics identify functional variants for rate of change in hippocampal volume in mild cognitive impairment, Mol. Psychiatry, vol.18, pp.781-787, 2013. ,
Co-development of diagnostic vectors to support targeted therapies and theranostics: essential tools in personalized cancer therapy, Front. Oncol, vol.4, p.141, 2014. ,
Blood-based biomarkers in Alzheimer disease: current state of the science and a novel collaborative paradigm for advancing from discovery to clinic, Alzheimers Dement, vol.13, pp.45-58, 2017. ,
Liquid biopsy and minimal residual disease -latest advances and implications for cure, Nat. Rev. Clin. Oncol, 2019. ,
Plasma tau/amyloid-beta1-42 ratio predicts brain tau deposition and neurodegeneration in Alzheimer's disease, Brain, vol.142, pp.771-786, 2019. ,
Untangling genetic risk for Alzheimer's Disease, Biol. Psychiatry, vol.83, pp.300-310, 2018. ,
Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease, Nat. Med, vol.25, pp.277-283, 2019. ,
Plasma neuronal exosomes serve as biomarkers of cognitive impairment in HIV infection and Alzheimer's disease, J. Neurovirol, 2019. ,
The druggable genome: evaluation of drug targets in clinical trials suggests major shifts in molecular class and indication, Annu. Rev. Pharmacol. Toxicol, vol.54, pp.9-26, 2014. ,
A humanized clinically calibrated quantitative systems pharmacology model for hypokinetic motor symptoms in parkinson's disease, Front. Pharmacol, vol.7, p.6, 2016. ,
Spatiotemporal diversification of intrapatient genomic clones and early drug development concepts realize the roadmap of precision cancer medicine, Drug Discov. Today, vol.22, pp.1148-1164, 2017. ,
Biochemical and functional characterization of germ line KRAS mutations, Mol. Cell. Biol, vol.27, pp.7765-7770, 2007. ,
increased plasma beta-secretase 1 may predict conversion to Alzheimer's disease dementia in individuals with mild cognitive impairment, Biol. Psychiatry, vol.83, pp.447-455, 2018. ,
Developing novel blood-based biomarkers for Alzheimer's disease, Alzheimers Dement, vol.10, pp.109-114, 2014. ,
MiRNA expression profiles in cerebrospinal fluid and blood of patients with Alzheimer's disease and other types of dementia -an exploratory study, Transl. Neurodegener, vol.5, p.6, 2016. ,
Drug-biomarker codevelopment in oncology -20 years and counting, Drug Resist. Updat, vol.30, pp.48-62, 2017. ,
Association of cerebrospinal fluid alpha-synuclein with total and phospho-tau181 protein concentrations and brain amyloid load in cognitively normal subjective memory complainers stratified by Alzheimer's disease biomarkers, Alzheimers Dement, vol.14, pp.1623-1631, 2018. ,
Liquid biopsies come of age: towards implementation of circulating tumour DNA, Nat. Rev. Cancer, vol.17, pp.223-238, 2017. ,
Network motifs modulate druggability of cellular targets, Sci. Rep, vol.6, p.36626, 2016. ,
Anti-microRNAs as novel therapeutic agents in the clinical management of Alzheimer's Disease, Front. Neurosci, vol.10, p.59, 2016. ,
He is co-inventor in the following patents as a scientific expert and has received no royalties: ? In Vitro Multiparameter Determination Method for The Diagnosis and Early Diagnosis of Neurodegenerative Disorders Patent Number: 8916388. ? In, Vitro Procedure for Diagnosis and Early Diagnosis of Neurodegenerative Diseases Patent Number: 8298784. Neurodegenerative Markers for Psychiatric Conditions Publication Number: 20120196300. ? In Vitro Multiparameter Determination Method for The Diagnosis and Early Diagnosis of Neurodegenerative Disorders Publication Number: 20100062463. ? In Vitro Method for The Diagnosis and Early Diagnosis of Neurodegenerative Disorders Publication Number: 20100035286. ? In Vitro Procedure for Diagnosis and Early Diagnosis of Neurodegenerative Diseases Publication Number: 20090263822. ? In Vitro Method for The Diagnosis of Neurodegenerative Diseases Patent Number: 7547553. CSF Diagnostic in vitro Method for Diagnosis of Dementias and Neuroinflammatory Diseases Publication Number: 20080206797. ? In Vitro Method for The Diagnosis of Neurodegenerative Diseases Publication Number ,
, ? Neurodegenerative Markers for Psychiatric Conditions Publication